日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers

抑制剂库筛选确定 ispinesib 是一种治疗胰腺癌的新型潜在化疗药物

Yoshiki Murase, Hiroaki Ono, Kosuke Ogawa, Risa Yoshioka, Yoshiya Ishikawa, Hiroki Ueda, Keiichi Akahoshi, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe

C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer

C646 抑制 G2/M 细胞周期相关蛋白并增强胰腺癌的抗肿瘤作用

Hiroaki Ono, Tomotaka Kato, Yoshiki Murase, Yutaro Nakamura, Yoshiya Ishikawa, Shuichi Watanabe, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Atsushi Kudo, Yoshimitsu Akiyama, Shinji Tanaka, Hiromichi Ito, Minoru Tanabe

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells

细胞质 RRM1 激活是吉西他滨治疗的急性反应,与胰腺癌细胞的耐药性有关

Tomotaka Kato, Hiroaki Ono, Mikiya Fujii, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe

Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma

在恶性胆管癌亚型中,ARID1A 的缺失会诱导干细胞基因 ALDH1A1 的表达和组蛋白乙酰化

Jun Yoshino, Yoshimitsu Akiyama, Shu Shimada, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shoji Yamaoka, Minoru Tanabe, Shinji Tanaka

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality

KDM6A 的缺失是人类胰腺癌预后不良亚型的特征,并增强了 HDAC 抑制剂的致死率

Shuichi Watanabe, Shu Shimada, Yoshimitsu Akiyama, Yoshiya Ishikawa, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shoji Yamaoka, Minoru Tanabe, Shinji Tanaka

Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients

乳清酸磷酸核糖基转移酶作为胆管癌患者 S-1 辅助化疗获益的预测指标

Keiichi Akahoshi, Daisuke Ban, Ryo Kuboki, Atsushi Oba, Hiroaki Ono, Yusuke Mitsunori, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe

Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors

具有代谢风险因素的肝细胞癌内肝星状细胞中脂肪酸结合蛋白 4 (FABP4) 过度表达

Norimichi Chiyonobu, Shu Shimada, Yoshimitsu Akiyama, Kaoru Mogushi, Michiko Itoh, Keiichi Akahoshi, Satoshi Matsumura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shigeki Arii, Takayoshi Suganami, Shoji Yamaoka, Yoshihiro Ogawa, Minoru Tanabe, Shinji Tanaka

Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs

DAXX 通过组蛋白 H3.3/H3K9me3 通路在胰腺 NET 中发挥肿瘤抑制作用

Hiroki Ueda, Yoshimitsu Akiyama, Shu Shimada, Kaoru Mogushi, Misaki Serizawa, Satoshi Matsumura, Yusuke Mitsunori, Arihiro Aihara, Daisuke Ban, Takanori Ochiai, Atsushi Kudo, Minoru Tanabe, Shinji Tanaka

DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma

DEPDC5 缺乏通过肝细胞癌中的 p62 积累增强对亮氨酸饥饿的抵抗力

Yuki Mizuno, Shu Shimada, Yoshimitsu Akiyama, Shuichi Watanabe, Tomomi Aida, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shigeki Arii, Shoji Yamaoka, Minoru Tanabe, Shinji Tanaka

Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma

生物标志物在胰腺导管腺癌辅助化疗选择中的临床应用

Atsushi Oba, Daisuke Ban, Susumu Kirimura, Keiichi Akahoshi, Yusuke Mitsunori, Satoshi Matsumura, Takanori Ochiai, Atsushi Kudo, Shinji Tanaka, Tanabe Minoru